{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:06:20Z","timestamp":1764403580642,"version":"3.46.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00702-4","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:39:21Z","timestamp":1762245561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deep learning-guided rational engineering of synergistic PD-1 and LAG-3 blockade for enhanced tumor immunomodulation"],"prefix":"10.1007","volume":"39","author":[{"given":"Shanza","family":"Mazhar","sequence":"first","affiliation":[]},{"given":"Taskeen","family":"Koser","sequence":"additional","affiliation":[]},{"given":"Rana Rehan","family":"Khalid","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"702_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/471561a","volume":"471","author":"H Ledford","year":"2011","unstructured":"Ledford H (2011) Melanoma drug wins US approval. Nature 471:561\u2013561","journal-title":"Nature"},{"key":"702_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y (2021) Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 14:45","journal-title":"J Hematol Oncol"},{"key":"702_CR3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10147-019-01588-7","volume":"25","author":"K Chamoto","year":"2020","unstructured":"Chamoto K, Hatae R, Honjo T (2020) Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol 25:790\u2013800","journal-title":"Int J Clin Oncol"},{"key":"702_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.18632\/genesandcancer.180","volume":"9","author":"L Long","year":"2018","unstructured":"Long L et al (2018) The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer 9:176\u2013189","journal-title":"Genes Cancer"},{"key":"702_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114824","volume":"163","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K, Majidpoor J (2023) Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1. Biomed Pharmacother 163:114824","journal-title":"Biomed Pharmacother"},{"key":"702_CR6","doi-asserted-by":"publisher","first-page":"35297","DOI":"10.1038\/srep35297","volume":"6","author":"S Horita","year":"2016","unstructured":"Horita S et al (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. Sci Rep 6:35297","journal-title":"Sci Rep"},{"key":"702_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"A Zhang","year":"2024","unstructured":"Zhang A et al (2024) Regulatory T cells in immune checkpoint blockade antitumor therapy. Mol Cancer 23:251","journal-title":"Mol Cancer"},{"key":"702_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.831407","author":"Y Wei","year":"2022","unstructured":"Wei Y, Li Z (2022) LAG3-PD-1 combo overcome the disadvantage of drug resistance. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.831407","journal-title":"Front Oncol"},{"issue":"D1","key":"702_CR9","doi-asserted-by":"publisher","first-page":"D383","DOI":"10.1093\/nar\/gkz827","volume":"48","author":"MIJ Raybould","year":"2020","unstructured":"Raybould MIJ et al (2020) Thera-SAbDab: the therapeutic structural antibody database. Nucleic Acids Res 48(D1):D383\u2013D388","journal-title":"Nucleic Acids Res"},{"key":"702_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0078-9","volume":"3","author":"L Khoja","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM (2015) Pembrolizumab. J Immunother Cancer 3:36","journal-title":"J Immunother Cancer"},{"key":"702_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000530","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A et al (2020) A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti\u2013PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 8:e000530","journal-title":"J Immunother Cancer"},{"key":"702_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1158\/1535-7163.MCT-20-0093","volume":"19","author":"AA Al-Khami","year":"2020","unstructured":"Al-Khami AA et al (2020) Pharmacologic properties and preclinical activity of sasanlimab, a high-affinity engineered anti-human PD-1 antibody. Mol Cancer Ther 19:2105\u20132116","journal-title":"Mol Cancer Ther"},{"key":"702_CR13","doi-asserted-by":"publisher","first-page":"S1598","DOI":"10.1016\/j.annonc.2022.10.431","volume":"33","author":"O Hamid","year":"2022","unstructured":"Hamid O et al (2022) 400P phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel). Ann Oncol 33:S1598","journal-title":"Ann Oncol"},{"key":"702_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003776","volume":"10","author":"P Sch\u00f6ffski","year":"2022","unstructured":"Sch\u00f6ffski P et al (2022) Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer 10:e003776","journal-title":"J Immunother Cancer"},{"key":"702_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J (2022) Nivolumab plus relatlimab: first approval. Drugs 82:925\u2013931","journal-title":"Drugs"},{"key":"702_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s42003-023-04927-7","volume":"6","author":"B Abanades","year":"2023","unstructured":"Abanades B et al (2023) Immunebuilder: Deep-learning models for predicting the structures of immune proteins. Commun Biol 6:575","journal-title":"Commun Biol"},{"key":"702_CR17","doi-asserted-by":"publisher","first-page":"14369","DOI":"10.1038\/ncomms14369","volume":"8","author":"S Tan","year":"2017","unstructured":"Tan S et al (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun 8:14369","journal-title":"Nat Commun"},{"key":"702_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jsb.2011.09.006","volume":"179","author":"Z Yang","year":"2012","unstructured":"Yang Z et al (2012) UCSF chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol 179:269\u2013278","journal-title":"J Struct Biol"},{"key":"702_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/prot.22570","volume":"77","author":"E Krieger","year":"2009","unstructured":"Krieger E et al (2009) Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: four approaches that performed well in CASP8. Proteins Struct Funct Bioinform 77:114\u2013122","journal-title":"Proteins Struct Funct Bioinform"},{"key":"702_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas J et al (2022) Robust deep learning\u2013based protein sequence design using ProteinMPNN. Science 378:49\u201356","journal-title":"Science"},{"key":"702_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/bioinformatics\/btab596","volume":"38","author":"S Grudman","year":"2021","unstructured":"Grudman S, Fajardo JE, Fiser A (2021) Intercaat: identifying interface residues between macromolecules. Bioinformatics 38:554\u2013555","journal-title":"Bioinformatics"},{"key":"702_CR22","doi-asserted-by":"publisher","first-page":"W382","DOI":"10.1093\/nar\/gki387","volume":"33","author":"J Schymkowitz","year":"2005","unstructured":"Schymkowitz J et al (2005) The FoldX web server: an online force field. Nucleic Acids Res 33:W382-388","journal-title":"Nucleic Acids Res"},{"key":"702_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.csbj.2018.01.002","volume":"16","author":"O Bu\u00df","year":"2018","unstructured":"Bu\u00df O, Rudat J, Ochsenreither K (2018) FoldX as protein engineering tool: better than random based approaches? Comput Struct Biotechnol J 16:25\u201333","journal-title":"Comput Struct Biotechnol J"},{"key":"702_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12859-023-05537-0","volume":"24","author":"Y Sapozhnikov","year":"2023","unstructured":"Sapozhnikov Y, Patel JS, Ytreberg FM, Miller CR (2023) Statistical modeling to quantify the uncertainty of FoldX-predicted protein folding and binding stability. BMC Bioinformatics 24:426","journal-title":"BMC Bioinformatics"},{"key":"702_CR25","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.jmb.2019.02.028","volume":"431","author":"R Pearce","year":"2019","unstructured":"Pearce R, Huang X, Setiawan D, Zhang Y (2019) Evodesign: designing protein-protein binding interactions using evolutionary interface profiles in conjunction with an optimized physical energy function. J Mol Biol 431:2467\u20132476","journal-title":"J Mol Biol"},{"key":"702_CR26","volume":"7","author":"A Vangone","year":"2017","unstructured":"Vangone A, Bonvin AMJJ (2017) PRODIGY: a contact-based predictor of binding affinity in protein-protein complexes. Bio-Protoc 7:e2124","journal-title":"Bio-Protoc"},{"key":"702_CR27","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1093\/bioinformatics\/btw514","volume":"32","author":"LC Xue","year":"2016","unstructured":"Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, Vangone A (2016) PRODIGY: a web server for predicting the binding affinity of protein\u2013protein complexes. Bioinformatics 32:3676\u20133678","journal-title":"Bioinformatics"},{"key":"702_CR28","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1021\/acs.jcim.2c01499","volume":"63","author":"YX Yang","year":"2023","unstructured":"Yang YX, Huang JY, Wang P, Zhu BT (2023) Area-affinity: a web server for machine learning-based prediction of protein-protein and antibody-protein antigen binding affinities. J Chem Inf Model 63:3230\u20133237","journal-title":"J Chem Inf Model"},{"key":"702_CR29","doi-asserted-by":"publisher","first-page":"W469","DOI":"10.1093\/nar\/gkw458","volume":"44","author":"DEV Pires","year":"2016","unstructured":"Pires DEV, Ascher DB (2016) Mcsm-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures. Nucleic Acids Res 44:W469-473","journal-title":"Nucleic Acids Res"},{"key":"702_CR30","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","volume":"63","author":"DA Case","year":"2023","unstructured":"Case DA et al (2023) AmberTools. J Chem Inf Model 63:6183\u20136191","journal-title":"J Chem Inf Model"},{"key":"702_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","volume":"16","author":"C Tian","year":"2020","unstructured":"Tian C et al (2020) ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J Chem Theory Comput 16:528\u2013552","journal-title":"J Chem Theory Comput"},{"key":"702_CR32","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/jp003020w","volume":"105","author":"P Mark","year":"2001","unstructured":"Mark P, Nilsson L (2001) Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K. J Phys Chem A 105:9954\u20139960","journal-title":"J Phys Chem A"},{"key":"702_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110010","volume":"756","author":"H Khizer","year":"2024","unstructured":"Khizer H, Maryam A, Ansari A, Ahmad MS, Khalid RR (2024) Leveraging shape screening and molecular dynamics simulations to optimize PARP1-specific chemo\/radio-potentiators for antitumor drug design. Arch Biochem Biophys 756:110010","journal-title":"Arch Biochem Biophys"},{"key":"702_CR34","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1016\/S0969-2126(99)80033-1","volume":"7","author":"T Darden","year":"1999","unstructured":"Darden T, Perera L, Li L, Pedersen L (1999) New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Structure 7:R55\u2013R60","journal-title":"Structure"},{"key":"702_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jcp.2006.05.032","volume":"220","author":"P Gonnet","year":"2007","unstructured":"Gonnet P (2007) P-SHAKE: a quadratically convergent SHAKE in. J Comput Phys 220:740\u2013750","journal-title":"J Comput Phys"},{"key":"702_CR36","unstructured":"Yao X-Q, Scarabelli G, Skjaerven L, Grant BJ. Protein structure networks with Bio3D."},{"key":"702_CR37","doi-asserted-by":"publisher","first-page":"W300","DOI":"10.1093\/nar\/gkz321","volume":"47","author":"A Kuriata","year":"2019","unstructured":"Kuriata A et al (2019) Aggrescan3D (A3D) 2.0: prediction and engineering of protein solubility. Nucleic Acids Res 47:W300\u2013W307","journal-title":"Nucleic Acids Res"},{"key":"702_CR38","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M (2020) NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res 48:W449\u2013W454","journal-title":"Nucleic Acids Res"},{"key":"702_CR39","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.1080\/07391102.2023.2242491","volume":"42","author":"A Maryam","year":"2024","unstructured":"Maryam A, Siddiqi AR, Chaitanya Vedithi S, Ece A, Khalid RR (2024) Identification of selective inhibitors for phosphodiesterase 5A using e-pharmacophore modelling and large-scale virtual screening-based structure guided drug discovery approaches. J Biomol Struct Dyn 42:7812\u20137827","journal-title":"J Biomol Struct Dyn"},{"key":"702_CR40","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TEI (2013) Ptraj and cpptraj: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9:3084\u20133095","journal-title":"J Chem Theory Comput"},{"key":"702_CR41","doi-asserted-by":"publisher","first-page":"W306","DOI":"10.1093\/nar\/gkae337","volume":"52","author":"A Del Conte","year":"2024","unstructured":"Del Conte A et al (2024) RING 4.0: faster residue interaction networks with novel interaction types across over 35,000 different chemical structures. Nucleic Acids Res 52:W306\u2013W312","journal-title":"Nucleic Acids Res"},{"key":"702_CR42","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BRI Miller","year":"2012","unstructured":"Miller BRI et al (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 8:3314\u20133321","journal-title":"J Chem Theory Comput"},{"key":"702_CR43","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.1080\/07391102.2021.1877818","volume":"40","author":"RR Khalid","year":"2022","unstructured":"Khalid RR, Maryam A, \u00c7\u0131naro\u011flu SS, Siddiqi AR, Sezerman OU (2022) A recursive molecular docking coupled with energy-based pose-rescoring and MD simulations to identify h sGC \u03b2H-NOX allosteric modulators for cardiovascular dysfunctions. J Biomol Struct Dyn 40:6128\u20136150","journal-title":"J Biomol Struct Dyn"},{"key":"702_CR44","doi-asserted-by":"publisher","first-page":"9488","DOI":"10.1038\/s41598-020-66310-4","volume":"10","author":"RR Khalid","year":"2020","unstructured":"Khalid RR et al (2020) Probing the structural dynamics of the catalytic domain of human soluble guanylate cyclase. Sci Rep 10:9488","journal-title":"Sci Rep"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00702-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:02:04Z","timestamp":1764403324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00702-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00702-4","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"118"}}